trifarotene · Galderma Labs Lp · NDA 211527
Aklief
Earliest generic entry, as listed
30 May 2033
Blocked by patent: US 9084778, US 9498465.
Listed patents · 3 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 9084778 | product, use U-134 | 30 May 2033 |
| US 9498465 | product, use U-1033 | 30 May 2033 |
| US 7807708 | substance, product | 19 Jul 2031 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 211527 · 001 · RLD | cream, topical | 0.005% | 30 May 2033 |